Latest Share Chat

CLIN.L Share News (CLIN)

CLIN.L Information

There is currently no data for CLIN

Clinigen Group's acquisitions boost first half growth

Tue, 19th Jan 2016 09:23

(ShareCast News) - Clinigen Group says it has had a solid first half performance, driven by acquisitions and organic growth.The AIM-listed company issued a trading update for the six months to 31 December on Tuesday.It said revenue had risen 116% and it had doubled its gross profit from last year due to the acquisitions of Idis in April and Link Healthcare in October.The revitalisation of newer products, Cardioxane, Savene and Ethyol also boosted profits in its Specialty Pharmaceuticals division, which makes up 33% of the group's gross profit, the company's strongest growth.Clinigen Group also said company is trading in line with the Board's expectations and is positioned for a good second half of the financial year.Chief executive Peter George said it has been an important six months for the company."The integration of Idis is on plan and the addition of Link Healthcare substantially strengthens our footprint in Africa, Australasia and Asia."These acquisitions established us as the global market leader in the management of unlicensed medicine and provide a broad platform for considerable organic growth opportunities in the future."

More News

14 Jul 2020 09:07

Clinigen FY revenues continue to rise, profit growth slowed by Covid-19

(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug.

13 Jul 2020 16:29

Clinigen gets orphan drug designation for 'aldesleukin' in the US

(Sharecast News) - Pharmaceutical services company Clinigen Group announced on Monday that the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted orphan drug designation for 'aldesleukin', in the treatment of amyotrophic lateral sclerosis (ALS).

13 Jul 2020 13:48

Monday broker round-up

(Sharecast News) - Kingfisher: RBC Capital Markets reiterates outperform with a target price of 275.0p

13 Jul 2020 08:41

Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin

14 Jun 2020 19:22

Sunday newspaper round-up: Two meters, Rolls Royce, Clinigen

(Sharecast News) - Senior scientists have reported flaws in an influential World Health Organization-commissioned study into the risks of coronavirus infection and say it should not be used as evidence for relaxing the UK's 2-metre physical distancing rule. Critics of the distancing advice, which states that people should keep at least 2 metres apart, believe it is too cautious. They seized on the research commissioned by the WHO, which suggested a reduction from 2 metres to 1 would raise infection risk only marginally, from 1.3% to 2.6%. - Guardian

28 May 2020 13:34